Previous close | 28.10 |
Open | 28.10 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 110.00 |
Expiry date | 2025-06-20 |
Day's range | 28.10 - 28.10 |
Contract range | N/A |
Volume | |
Open interest | N/A |
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered. Mainz Biomed N.V. (NASDAQ: MYNZ) to revolutionize c
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.